This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Symplmed Pharmaceuticals LLC
Drug Names(s): Perindopril Erbumine, Coversyl
Description: Aceon belongs to a family of drugs called angiotensin converting enzyme (ACE) inhibitors. They work by preventing angiotensin I from converting into a more potent form that increases salt and water retention in the body and constricts blood vessels, though other mechanisms, such as inhibiting the degradation of the vasodilator bradykinin, may be involved in their longer term effects. Some ACEIs, including Aceon, have also been found to reduce cardiovascular events in patients with elevated risk.
CV Therapeutics and Solvay Pharmaceuticals entered into a co-promotion agreement for ACEON in December 2004. The co-promotion agreement covers the United States and extends through at least 2010. CV Therapeutics is responsible for brand marketing activities and has established a cardiovascular specialtysales force to promote the product. Solvay Pharmaceuticals continues to handlethe manufacturing and distribution of the product, and its primary care salesforce also continues to promote the product.
Solvay Pharmaceuticals will book all sales of ACEON and CV Therapeutics will receive a royalty in the approximate range of 50% to 60% on all sales above a pre-specified baseline level of sales. This baseline approximates the current annual sales level of ACEON , which is in the range of $30 million. There are no upfront payments by either party associated with the co-promotion agreement.
On October 11, 2006 CV Therapeutics announced that it has sent Solvay Pharmaceuticals a...See full deal structure in Biomedtracker
Partners: AbbVie Inc. XOMA Corporation
Pink Sheet Aceon aces supplemental review
Additional information available to subscribers only: